Molecular Imaging

The Molecular Imaging group focuses on the visualization of Alzheimer’s disease (AD) related changes in the brain of mouse models using in vivo multiphoton microscopy. A solid knowledge of the dynamics of amyloid lesions and associated neurodegeneration and neuroinflammatiuon is essential for the understanding of disease pathomechanisms and also critical for the interpretation of amyloid imaging in AD clinical studies.

Main objectives
Recent results
Publications
Staff

1. To investigate the development of amyloid lesions and associated pathologies in vivo in the mouse brain.

2. To characterize novel amyloid-binding dyes with respect to their staining properties of different amyloid types.

3. To study microglial behavior in the living brain, both in the context of normal aging and in mouse models of neurodegeneration.

To this end, we use a variety of transgenic mouse models of cerebral amyloidoses in combination with endogenously fluorophore-labeled microglia and/or neuronal subpopulations. In vivo examination is performed using multiphoton microscopy combined with a set of advanced imaging tools for stereological and 5D analysis of the morphological datasets.

We have used multiphoton in vivo imaging to study Aβ plaque formation in the brains of APPPS1 transgenic mice. By using a newly designed head fixation system (Hefendehl et al., J Neurosci Methods 2012) with automatic rapid repositioning to previously marked areas, we have successfully identified newly appearing amyloid deposits and tracked single amyloid plaques for up to 6 months. The results revealed that newly formed amyloid plaques develop in young APPPS1 transgenic mice at an estimated rate of 35 per mm3 of neocortical volume per week. At later time-points, i.e. with increasing cerebral β-amyloidosis, the number of newly formed plaques declines in comparison to the early phases of amyloid deposition. Both newly formed and existing plaques grow with a similar weekly increase of 0.3 μm in radius over the entire imaging period. These results suggest that amyloid plaque formation is a spontaneous process that is likely dependent on the local concentration of Aβ, which in turn is in dynamic equilibrium with the insoluble Aβ in plaques (Hefendehl et al., J Neuroscience 2011). A solid knowledge of the dynamics of cerebral amyloidosis in the mouse models is instrumental for testing amyloid-interfering compounds in such in vivo settings.

Once Aβ aggregation has started, microglia move toward the amyloid and adopt a phagocytic morphology (Bolmont et al., J Neuroscience 2008). Independent of amyloid deposits, we recently showed that microglial cells exhibit an age-related loss of homogeneous tissue distribution, and that the movement of microglial somata increases in aged mice. However, in response to tissue injury the microglial response is age-dependently diminished (Hefendehl et al., Aging Cell, 2013).

Although various amyloids share a common three-dimensional structure with similar chemical and biophysical properties, they can exhibit conformational variations that cannot be distinguished using classical amyloid-binding dyes. In a recent study, we demonstrated that a novel class of amyloid-binding dyes (LCOs) cross the blood brain barrier and stain all major AD amyloid lesions in the brain (plaques, vascular amyloid, tau inclusions). Furthermore, because LCOs exhibit a conformation-dependent spectral shift of their emitted fluorescence, they allow for spectral discrimination of structurally different amyloid lesions also upon two-photon excitation (Wegenast-Braun et al., Am J Pathol 2012). Current studies are assessing whether LCOs are also effective in distinguishing structural variations within the same lesion, e.g. due to changes in amyloid composition/structure as a function of disease progression. The effective separation of amyloid (sub)types may provide further insight into the linkage of distinct conformational amyloid structures to in vivo malfunctions.

Contact: Bettina Wegenast-Braun, Angelos Skodras 

 

 

Hefendehl JK, Neher JJ, Sühs RB, Kohsaka S, Skodras A, Jucker M (2014) Homeostatic and injury-induced microglia behavior in the aging brain. Aging Cell 13:60-9 (Abstract)

Wegenast-Braun BM, Skodras A, Bayraktar G, Mahler J, Fritschi SK, Klingstedt T, Mason JJ, Hammarstrom P, Nilsson KP, Liebig C, Jucker M (2012) Spectral discrimination of cerebral amyloid lesions after peripheral application of luminescent conjugated oligothiophenes. Am J Pathol 181:1953-60 (Abstract)

Hefendehl JK, Milford D, Eicke D, Wegenast-Braun BM, Calhoun ME, Grathwohl SA, Jucker M, Liebig C (2012)  Repeatable target localization for long-term in vivo imaging of mice with 2-photon microscopy. J Neurosci Meth 205:357-63 (Abstract)

Hefendehl JK*, Wegenast-Braun BM*, Liebig C, Eicke D, Milford D, Calhoun ME, Kohsaka S, Eichner M, Jucker M (2011) Long-term in vivo imaging of β-amyloid plaque appearance and growth in a mouse model of cerebral β-amyloidosis. J Neuroscience 31:624-9 (Abstract)


 
Name
Arbeitsgruppe
Telefon
E-Mail
 Natalie Beschorner
Natalie Beschorner PhD Student
Molecular Imaging
07071 29-81945 
Dr. Angelos Skodras
Dr. Angelos Skodras PostDoc (DZNE)
Molecular Imaging
07071 29-87606 
Dr. Bettina Wegenast-Braun
Dr. Bettina Wegenast-Braun PostDoc
Molecular Imaging
07071 29-87607 
Ansprechpartner
Dr. Angelos Skodras angelos.skodrasdzne.de Anschrift

Zentrum für Neurologie
Hertie-Institut für klinische Hirnforschung
Abteilung Zellbiologie neurologischer Erkrankungen

Otfried-Müller-Straße 27
72076 Tübingen

Tel.: +49 (0)7071 29-87607
Fax: +49 (0)7071 29-4521